Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated ...